Navigation Links
Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda
Date:4/29/2013

WELWYN GARDEN CITY, England and BOSTON, April 29, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved all milestones in its collaboration with Takeda Pharmaceutical Company. By achieving these milestones, Heptares will receive a significant payment from Takeda, under the terms of the agreement signed by the two companies in 2011.

The agreement is focused on a single GPCR target nominated by Takeda that, until now, has proved intractable to rational drug discovery efforts due to its instability when removed from the cell membranes and the resulting lack of insight into its structure. Over the course of the collaboration Heptares has leveraged its structure-based drug design (SBDD) approach to GPCRs and proprietary technologies to generate the first-ever stabilised form of the target in a clinically relevant conformation enabling a series of novel lead candidates against the target to be designed.

Tetsuyuki Maruyama , General Manager Pharmaceutical Research Division, Takeda said: "We are impressed with the efficiency and results from this partnership with Heptares. In achieving these milestones, the Heptares team has demonstrated its ability to design new, high-quality small molecules to a previously challenging GPCR target. We look forward to continuing our partnership and taking these leads forward into pre-clinical development."

"Our partnership with Takeda provides an excellent validation of our GPCR-focused structure-based drug design approach and capabilities," said Malcolm Weir , CEO of Heptares. "We see similar good progress in our other partnerships where to date we have hit every milestone. This success, in turn, provides us with an important source of capital, which has enabled us to build an impressive proprietary pi
'/>"/>

SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
2. Heptares Solves First Family B GPCR Structure
3. Heptares to Present at BIO-Europe 2012
4. Heptares to Moderate Panel on Rare Diseases at BBC New York CEO Meeting (13-14 February)
5. Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
6. GenVec Achieves Second Milestone in Collaboration
7. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
8. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
9. TriCore Solutions Achieves SAP Gold Partner Status
10. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
11. Idem Translations Achieves ISO 13485:2003 Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... McKinney, Texas (PRWEB) May 28, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be attending the World Pork Expo, June 3-5 ... earlier this year in a Wall Street Journal ...
(Date:5/28/2015)... NORTH BRUNSWICK, N.J. , May 28, 2015 ... that PDS0101, a cancer immunotherapy treatment targeting HPV-16, ... patients.  Currently, pre-cervical cancer is ... could offer a simple and effective non-surgical alternative. ... body,s defense mechanisms (T-cells) to recognize, target, and ...
(Date:5/28/2015)... BEACH, Fla. , May 28, 2015 ... supporting the anti-cancer potential of its growth hormone-releasing hormone ... at the 2015 ASCO Annual Meeting. The data ... target for Biscayne,s anti-cancer GHRH blockers, is present on ... status. These findings suggest that GHRH antagonists could have ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... April 15, 2011 Carmell Therapeutics, a company that ... of injured tissues, has closed on a Series A ... facility and collect data for early clinical validation for ... was led by Harbor Light Capital Partners, a private ...
... Therapeutics, Inc. (Nasdaq: HALO ) today announced ... patients who receive their insulin treatment with a ... Halozyme,s rHuPH20 (recombinant human hyaluronidase) with the active ingredient ... of action. These preliminary results represent the first reported ...
... Promising new devices for mechanical circulatory support of ... research, will be revealed this week at the International ... Meeting and Scientific Sessions. An update from the Pumps ... presented during the Meeting in San Diego.  PumpKIN is ...
Cached Biology Technology:Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 2Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 4Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 2Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 3
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... to tackle wheat,s worst enemy , Unlocking ancient rice ... in aphids, mouths, Reducing crop losses with cereals that ... better Indian varieties , Over 40 international research organisations ... will harness bioscience to improve food security in developing ...
... the physical process that creates that oh-so-alluring new car ... out, not particularly wholesome for sensitive satellite instruments, either. But ... to protect those instruments from its ill effects. ... car is its factory-fresh new car smell, a distinctive aroma ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... that its Board of Directors has declared a special cash ... total.  The special cash dividend will be paid on December ... 2012.  The Board of Directors has determined ...
Cached Biology News:Major international push to maximize bioscience research to help world's poorest farmers 2Major international push to maximize bioscience research to help world's poorest farmers 3Major international push to maximize bioscience research to help world's poorest farmers 4Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 2Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 3Aware, Inc. Declares Special Cash Dividend of $1.80 Per Share, or Approximately $40 Million in Total 2
... anti-Human Alpha 1 Acid Glycoprotein ... Goats were immunized with ... in Freund's adjuvant. The ... to ensure specificity. For ...
...
... Development kit contains the basic components required ... measure natural and recombinant canine Monocyte Chemotactic ... and serum.1 Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Biology Products: